Thanks for posting to downplay a significant development—we’ll try not to notice the update or talk about it too much 😶
It was not “just a name change”
On the newly updated NHS document that was just published, there were 4 changes in total—3 related to the entry corresponding to DCVax-L, and one additional noteworthy addition to the list:
✅️ Canpuldencel-T was updated to reflect the current INN for DCVax-L: murcidencel.
✅️ The indication was changed from “cancer glioblastoma” to the broader term “cancer.”
✅️ The final column before the notes column, titled “STATUS AS HCD,” was updated to indicate “NHSPS” (NHS Payment Scheme).
✅️ “AUTOLOGOUS DENDRITIC CELL VACCINE” was added as a separate and distinct entry. This category would include therapies such as the Roswell DC platform, DCVax-Direct, or other autologous DC technologies like variations that may be developed at UCLA. (Murcidencel is also autologous, but it specifically refers to the proprietary DCVax-L platform.)
The recent updates to the NHS High Cost Drugs (HCD) list involving murcidencel (formerly DCVax-L) are notable for several reasons:
1. Name Update: Canpuldencel-T was revised to reflect the therapy’s current International Nonproprietary Name (INN), murcidencel, aligning the listing with regulatory standards.
2. Broader Indication: The indication was changed from “cancer glioblastoma” to “cancer,” suggesting potential future applicability beyond glioblastoma, subject to supporting clinical evidence and regulatory approval.
3. NHSPS Status: The therapy’s status was updated to “NHSPS,” indicating it is now managed under the NHS Payment Scheme. This may enable more standardized funding and broader access.
4. New DC Vaccine Category: A separate entry for “Autologous Dendritic Cell Vaccine” was added. This broader category may include other platforms, such as those from Roswell Park and UCLA. While murcidencel is also autologous, its separate listing reflects its distinct regulatory and clinical profile.
Together, these updates signal the NHS’s increasing readiness to integrate advanced, personalized therapies into its care pathways.
Market Data 
Markets 
